Consensus ResMed Inc. Sao Paulo

Stocks

R1MD34

BRR1MDBDR003

Advanced Medical Equipment & Technology

Market Closed - Sao Paulo 10:58:13 2026-10-13 EDT			5-day change	1st Jan Change
294.47 ^BRL	+20.76%		0.00%	-11.93%

07:08pm	ASX Preview: Australian Shares to Rise as Oil Slips on US-Iran Peace Hopes; ResMed Fiscal Q1 Non-GAAP Earnings, Revenue Up	MT
10-29	ResMed Inc., Q1 2027 Earnings Call, Oct 29, 2026

778029d2a2180d32b9620.FKzDsswrEhte_9290mRZ1CICEv8XcJsnUle-RucBk2E.ffOt941qR3c7ub_spSY7-X1hXKtGCK5NCmTaf6tLojdn4LDYuXFKXhu56Q~23d21c266ea81bc4c889fcf8be79cd0f

Analysts' recommendations: ResMed Inc.

10-15	Baird Adjusts Price Target on ResMed to $238 From $213	MT
10-13	Mizuho Adjusts Price Target on ResMed to $240 From $235	MT
09-15	ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says	MT
09-15	RBC Upgrades ResMed to Outperform From Sector Perform, Raises Price Target to $262 From $244	MT
09-15	Analyst recommendations: Abercrombie & Fitch, Eli Lilly, Philip Morris, Ulta Beauty…
09-10	Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating	MT
09-03	Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating	MT
08-31	KeyBanc Adjusts Price Target on ResMed to $267 From $255, Keeps Overweight Rating	MT
08-19	Rothschild & Co Redburn Initiates ResMed at Neutral With $230 Price Target	MT
08-07	Jefferies Adjusts Price Target on ResMed to $220 From $225	MT
08-07	Mizuho Adjusts Price Target on ResMed to $235 From $220	MT
08-07	Morgan Stanley Adjusts Price Target on ResMed to $227 From $229	MT
08-07	KeyBanc Capital Adjusts Price Target on ResMed to $255 From $260	MT
08-07	Piper Sandler Adjusts Price Target on ResMed to $225 From $233	MT
08-07	Baird Adjusts Price Target on ResMed to $213 From $217	MT
08-07	Wells Fargo Adjusts Price Target on ResMed to $215 From $225	MT
08-07	RBC Capital Adjusts PT on ResMed to $244 From $234, Maintains Sector Perform Rating	MT
08-07	Analyst recommendations: Micron Technology, Lockheed Martin, Airbnb, Johnson Controls International, The Allstate Corporation…
07-24	BofA Adjusts Price Target on ResMed to $320 From $310	MT
07-21	ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says	MT
07-17	RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276	MT
07-15	Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating	MT
07-14	Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating	MT
07-13	Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270	MT
07-13	Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34	MT

More recommendations

Other Advanced Medical Equipment & Technology

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	THERMO FISHER SCIENTIFIC, INC.					+6.64%
	DANAHER CORPORATION					+11.04%
	INTUITIVE SURGICAL, INC.					+8.66%
	BOSTON SCIENTIFIC CORPORATION					+35.13%
	EDWARDS LIFESCIENCES CORPORATION					+10.47%
	SIEMENS HEALTHINEERS AG					+6.59%
	VEEVA SYSTEMS INC.					-5.26%
	AGILENT TECHNOLOGIES, INC.					+0.31%
	WATERS CORPORATION					-2.31%
	Average					+7.92%
	Weighted average by Cap.					+8.46%